CureVac appoints new chief development officer

CureVac NV
Appointee name
Myriam Mendila


CureVac NV of Germany has appointed Myriam Mendila as chief development officer, effective 1 February 2023, to succeed Klaus Edvardsen who is returning to his native country of Denmark. Dr Mendila has worked in the pharma industry for more than 20 years, including in the area of commercial strategy at Roche, Genentech and Novartis.

Most recently, she was head of medical affairs and chief medical officer, oncology at Novartis Pharma AG. Dr Mendila earned her medical degree and subsequently a doctoral degree from the Medical University of Hanover in Germany.

CureVac announced the appointment on 8 June 2022.

Copyright 2022 Evernow Publishing Ltd